Late-breaking trial: two-year clinical outcome data from SYNTAX II
On May 23, as part of the EuroPCR 2018 late-breaking trial program, professor Patrick Serruys of Imperial College London, UK, will present two-year clinical outcome data from the SYNTAX II trial. The trial, which included 454 patients from 22 centers across the United Kingdom, the Netherlands, Spain, and Poland, evaluated a state-of-the-art percutaneous coronary intervention (PCI) procedure that incorporates physiology, intravascular ultrasound (IVUS) imaging, drug-eluting stents and contemporary optimal medical therapy.
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
See Philips’ calendar of events for EuroPCR, including its Training Village program of hands-on experiences, live demonstrations and a symposium, here. Visit the Philips booth (F16, Level 1) to experience its innovative cardiology portfolio. Follow the #EuroPCR conversation on @PhilipsLiveFrom throughout the event.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.
Back to HCB News
